Featured Research

from universities, journals, and other organizations

Borrowing From Ebola Virus Could Aid Cystic Fibrosis Gene Therapy

Date:
May 1, 2003
Source:
University Of Iowa
Summary:
A problem with current efforts in developing a cystic fibrosis gene therapy is that delivering genes into airway cells is inefficient and requires disrupting the integrity of the cell layer. However, a finding by University of Iowa researchers and colleagues may help solve the problem by using a surprising tool -- a modified piece of the Ebola virus.

A problem with current efforts in developing a cystic fibrosis gene therapy is that delivering genes into airway cells is inefficient and requires disrupting the integrity of the cell layer. However, a finding by University of Iowa researchers and colleagues may help solve the problem by using a surprising tool -- a modified piece of the Ebola virus. The findings will appear in issue 10 (May) of the Journal of Virology.

The investigators found that taking a small part of the protein coat from the Ebola virus and putting it on another modified virus creates a hybrid vehicle that can attach itself to a receptor on the top surface, or airway side, of lung cells. The genes within the vehicle can then enter the host cell, where they integrate into the host chromosomes. Previously studied gene delivery vehicles can attach only to the bottom surface, which requires breaching the normally closed cell surface layer.

The discovery has implications for treating cystic fibrosis and other lung conditions where the genes needed for healthy lung function are mutated or absent.

"Most people understandably do not think of the Ebola virus in a favorable light, but our approach takes a small part from this bad virus and puts it in a hybrid system to get some good out it," said Paul McCray, M.D., UI professor of pediatrics and lead investigator of the study.

"A large region of the Ebola protein coat, or envelope, is deleted, so it is potentially safer to use," said Patrick Sinn, Ph.D., a UI post-doctoral fellow in pediatrics and the paper's lead author.

The investigation was done in healthy human airway cells that functionally mimic actual human airways. Clinical applications of the finding are only potential at this time.

"We still are multiple steps from knowing whether this Ebola-modified vector can deliver therapeutic genes into the airway cells of people with cystic fibrosis and correct the genetic defect," McCray cautioned. "However, we now have a new tool that allows us to get the virus into the cells without disrupting their integrity by targeting the cells from the air surface side."

People with cystic fibrosis have serious lung and digestive problems because of malfunctioning ion channels. These channels normally regulate salt and water secretions to protect the lungs. The channels are made by a specialized protein, but in people with cystic fibrosis the gene that codes for the protein is mutated. Thus, researchers aim to find ways to insert functional versions of the genes into the airway cells of people with the condition.

In their investigation, the researchers attached the Ebola protein piece to a modified feline immunodeficiency virus, which causes leukemia in cats but no disease in humans. When the hybrid virus is delivered to airway cells, the modified Ebola protein acts like a key that fits into a lock, or receptor, on the top surface of the airway cells. Because the protein piece can "fit" onto the top surface, the integrity of the cell layer is not affected, yet the gene products within the hybrid virus can enter the cell.

In contrast, other gene delivery vectors studied by McCray and others deliver genes by opening "tight junctions" in order to access the bottom surface of cells. Disrupting these junctions is not ideal.

"Normally, cells stick tightly to their neighbors. You can temporarily disrupt the junctions to allow something to pass between the cells; however, there are situations where opening them could be harmful," McCray said. "It may not be a big problem, but it is more desirable not to do it if you don't have to. Using the Ebola virus protein allows us to redirect the delivery virus to the top surface of the cell and avoid the disruption."

The researchers said another advantage of the shortened Ebola protein is that it increases the amount of virus that can be produced. That observation was made by one of the team's collaborators, David Sanders, Ph.D., associate professor of biological sciences at Purdue University.

"Increasing the amount of particles 100-fold becomes really important when you start to consider these viral particles as a drug," McCray said. "The increased production provides enough particles to make additional pre-clinical studies feasible."

The UI investigators eventually want to identify the receptor to which the modified Ebola protein binds. However, their immediate next step is to see how the hybrid virus functions in airway cells taken from people with cystic fibrosis.

The study was supported in part by funding from the National Institutes of Health (NIH) and the Cystic Fibrosis Foundation. In addition, Sinn was supported by a National Research Service Award from the NIH.

The Gene Transfer Vector Core, Cell Culture Core and Cell Morphology Core at the UI provided assistance to the investigators.

For more information about cystic fibrosis research, visit the UI Center for Gene Therapy for Cystic Fibrosis and Other Genetic Diseases at http://genetherapy.genetics.uiowa.edu/.

For more information about cystic fibrosis, visit the Cystic Fibrosis Foundation at http://www.cff.org/.

University of Iowa Health Care describes the partnership between the UI Roy J. and Lucille A. Carver College of Medicine and UI Hospitals and Clinics and the patient care, medical education and research programs and services they provide. Visit UI Health Care online at http://www.uihealthcare.com.


Story Source:

The above story is based on materials provided by University Of Iowa. Note: Materials may be edited for content and length.


Cite This Page:

University Of Iowa. "Borrowing From Ebola Virus Could Aid Cystic Fibrosis Gene Therapy." ScienceDaily. ScienceDaily, 1 May 2003. <www.sciencedaily.com/releases/2003/04/030430081442.htm>.
University Of Iowa. (2003, May 1). Borrowing From Ebola Virus Could Aid Cystic Fibrosis Gene Therapy. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2003/04/030430081442.htm
University Of Iowa. "Borrowing From Ebola Virus Could Aid Cystic Fibrosis Gene Therapy." ScienceDaily. www.sciencedaily.com/releases/2003/04/030430081442.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins